Alexander Gottschalk, MD, PhD

Director, Cyberknife Radiosurgery
Radiation oncologist

Dr. Alexander Gottschalk, an expert in radiation treatment, is director of UCSF's program in CyberKnife surgery, which uses a flexible robotic arm to precisely deliver high doses of radiation. Gottschalk uses the CyberKnife to treat cancers of the brain, spine, breast, chest, abdomen, kidney and pelvis. He employs other radiation techniques to treat urologic cancers, such as bladder and prostate cancer; gastrointestinal cancer, such as pancreatic cancer; soft tissue tumors, such as sarcomas; and thoracic cancers, such as lung cancer.

Gottschalk earned both his medical degree and doctorate at the University of Chicago. He completed a residency in radiation oncology at UCSF.

Gottschalk has received numerous awards and research grants, including a research service award and a medical scientist fellowship from the National Institutes of Health, a clinical research grant from the UCSF Helen Diller Family Comprehensive Cancer Center, a scholar award from the Radiological Society of North America and a junior faculty award from the American Society for Radiation Oncology.

Conditions & Treatments

More about Alexander Gottschalk

Education

University of Chicago School of Medicine 1996

Residencies

UCSF Medical Center, Radiation Oncology 2001

Selected Research and Publications

  1. Chapman CH, Braunstein SE, Pouliot J, Noworolski SM, Weinberg V, Cunha A, Kurhanewicz J, Gottschalk AR, Roach MI, Hsu IC. Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy. J Contemp Brachytherapy. 2018 Jun; 10(3):193-201.
  2. Chapman CH, McGuinness C, Gottschalk AR, Yom SS, Garsa AA, Anwar M, Braunstein SE, Sudhyadhom A, Keall P, Descovich M. Influence of respiratory motion management technique on radiation pneumonitis risk with robotic stereotactic body radiation therapy. J Appl Clin Med Phys. 2018 Apr 26.
  3. Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Taira AV, Vapiwala N, Davis BJ. ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):437-454.
  4. McLaughlin PW, Liss AL, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, Movsas B, Prestidge BR, Showalter TN, Taira AV, Vapiwala N, Davis BJ. ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer. Am J Clin Oncol. 2017 Feb; 40(1):1-10.
  5. Paulsson AK, Yom SS, Anwar M, Pinnaduwage D, Sudhyadhom A, Gottschalk AR, Chang AJ, Descovich M. Respiration-Induced Intraorgan Deformation of the Liver. Technol Cancer Res Treat. 2017 Jan 01; 1533034616687193.
  6. Davis BJ, Taira AV, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Showalter TN, Vapiwala N. ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. Brachytherapy. 2017 Mar - Apr; 16(2):266-276.
  7. ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. Adv Radiat Oncol. 2017 Jan-Mar; 2(1):62-84.
  8. Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M, Carroll PR. Correction: Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes. PLoS One. 2016; 11(10):e0164558.
  9. Woodard GA, Crockard JC, Clary-Macy C, Zoon-Besselink CT, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity. J Surg Oncol. 2016 Dec; 114(7):838-847.
  10. Zhang L, Johnson J, Gottschalk AR, Chang AJ, Hsu IC, Roach M, Seymour ZA. Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2017 Mar - Apr; 7(2):e109-e116.
  11. Wahl M, Descovich M, Shugard E, Pinnaduwage D, Sudhyadhom A, Chang A, Roach M, Gottschalk A, Chen J. Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer. Technol Cancer Res Treat. 2017 04; 16(2):178-187.
  12. Crehange G, Izaguirre A, Weinberg V, Hsu CC, Gottschalk AR, Hsu IC, Shinohara K, Carroll P, Roach M. Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery. Am J Clin Oncol. 2016 Apr; 39(2):167-72.
  13. Pinnaduwage DS, Descovich M, Lometti MW, Varad B, Roach M, Gottschalk AR. An Evaluation of Robotic and Conventional IMRT for Prostate Cancer: Potential for Dose Escalation. Technol Cancer Res Treat. 2017 06; 16(3):267-275.
  14. Anwar M, Weinberg V, Seymour Z, Hsu IJ, Roach M, Gottschalk AR. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer. Radiat Oncol. 2016 Jan 21; 11:8.
  15. McGuinness CM, Gottschalk AR, Lessard E, Nakamura JL, Pinnaduwage D, Pouliot J, Sims C, Descovich M. Investigating the clinical advantages of a robotic linac equipped with a multileaf collimator in the treatment of brain and prostate cancer patients. J Appl Clin Med Phys. 2015 09 08; 16(5):284–295.
  16. Tinkle CL, Weinberg V, Braunstein SE, Wustrack R, Horvai A, Jahan T, O'Donnell RJ, Gottschalk AR. Intraoperative Radiotherapy in the Management of Locally Recurrent Extremity Soft Tissue Sarcoma. Sarcoma. 2015; 2015:913565.
  17. Raleigh DR, Chang AJ, Tomlin B, Cunha JA, Braunstein SE, Shinohara K, Gottschalk AR, Roach M, Hsu IC. Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer. Brachytherapy. 2015 Nov-Dec; 14(6):795-800.
  18. Seymour ZA, Chang AJ, Zhang L, Kirby N, Descovich M, Roach M, Hsu IC, Gottschalk AR. Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2015 Sep-Oct; 5(5):e465-72.
  19. Descovich M, McGuinness C, Kannarunimit D, Chen J, Pinnaduwage D, Pouliot J, Kased N, Gottschalk AR, Yom SS. Comparison between target margins derived from 4DCT scans and real-time tumor motion tracking: insights from lung tumor patients treated with robotic radiosurgery. Med Phys. 2015 Mar; 42(3):1280-7.
  20. Gustafson GS, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Hsu IC, Lloyd S, Mclaughlin PW, Merrick GS, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis BJ. ACR appropriateness Criteria® Postradical prostatectomy irradiation in prostate cancer. Oncology (Williston Park). 2014 Dec; 28(12):1125-30, 1132-6.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.